Business Description
Helus Pharma is a Toronto-based clinical-stage company working to develop new treatments for mental health conditions using compounds derived from psychedelics. Its most advanced programs include a modified form of psilocybin currently in Phase 3 trials for major depression, and a DMT-based compound in Phase 2 trials for generalized anxiety disorder. The company has additional candidates at earlier stages of development and works with Segal Trials to run a large multinational study evaluating its lead depression treatment.
